Darren Wheeler, PhD

Intercept Pharmaceuticals, Inc.

Poster(s):

• P1754 - Effect of Obeticholic Acid on Reduction and Normalization of Alanine Aminotransferase and Aspartate Aminotransferase in the Phase 3 POISE Trial in Primary Biliary Cholangitis
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET

• P1755 - Association of Elevated Liver Biochemistries and Clinical Outcomes Within Strata of Alkaline Phosphatase Levels in Patients With Primary Biliary Cholangitis
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET

• P3491 - Evaluation of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index Stabilization in the Phase 3 POISE Trial of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P3492 - Stabilization of Enhanced Liver Fibrosis and Liver Stiffness Measures in the Open-Label Extension of the Phase 3 POISE Trial of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET